Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Review Djibouti .
Press releases published on August 29, 2025
Bispecific Antibody Drug Conjugates ADC Clinical Trials FDA Approval Companies Commercial Launch Report 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape and Market Opportunity Insight 2025 Report Findings and Highlights: First Bispecific Antibody Drug Conjugate …
Controlled Release Drug Delivery Market Size FDA Approved Drugs Clinical Trials Companies Report 2030
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Research Methodology Followed Global and Regional Market Overview Global …
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive …
OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale
OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale NANTES, France - 29 août 2025, 8h00 CET – OSE Immunotherapeutics SA (ISIN: …
Santhera schliesst Vereinbarung mit Ikris Pharma Network über den Vertrieb von AGAMREE® (Vamorolon) in Indien
Pratteln, Schweiz, 29. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Ikris Pharma Network (Ikris) über den Vertrieb von AGAMREE® (Vamorolon) in Indien zur Behandlung von Duchenne- …
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne …
American Rebel Holdings Clarifies: No Amended S-1 Filed on August 28; Webull/Benzinga Posts Mischaracterized Prior June 3 Filing
After fielding multiple investor calls prompted by misleading August 28 Benzinga posts, the Company confirms no new S-1/A was filed; the referenced amendment was filed June 3, 2025, and the referenced registration was declared effective June 27, 2025. …
STACK Infrastructure Reinforces Responsible Development Principles through Project Jupiter in New Mexico
DENVER, Aug. 28, 2025 (GLOBE NEWSWIRE) -- STACK Infrastructure (“STACK”), the digital infrastructure partner to the world’s most innovative companies and a leading global developer and operator of data centers, announced today its role in Project Jupiter, …
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. …